Using a fragment- and structure-based approach together with a flexible company structure, Sprint Bioscience can move in just months from target selection to compounds ready for testing in cell-based assays. This approach provides early pharmacological validation of new and highly relevant targets and builds up a valuable project portfolio.
Sprint Bioscience establishes early collaboration to ensure that projects are developed with a focus on current market needs from the start.
This is what we believe
Sprint Bioscience was founded on the belief that drug discovery can be improved by combining well-trimmed organizations with highly skilled specialists. We put together small teams of experienced people with just the right skills. They work closely together in a stimulating, focused environment.
Sprint Bioscience has the possibility to not only move quickly but also to combine the most promising therapeutic angle with today’s frontline drug discovery technology.
We work on cancer metabolism
Targeting the metabolism of cancer provides exciting opportunities to develop drug therapies with novel mechanisms of action. This could be used to overcome one of the major problems of current cancer therapy – the development of resistance to treatments by cancer cells.
In a new emerging area such as cancer metabolism, speed is even more of the essence than usual. Our strength lies in being able to rapidly pan for druggable targets in the target space and develop active molecules for concept evaluation.
Sprint Bioscience has established an efficient process and platform that can take us in a very short time from idea to active molecules ready for testing in cell-based systems.
Sprint Bioscience in action
Sprint Bioscience AB is led by people with extensive experience from the pharmaceutical industry, particularly in structure-based drug discovery. Sprint Bioscience has been able to attract top researchers with a shared philosophy on quality and efficiency of lead discovery.
We are a fully-equipped drug development unit with expertise from target expression to delivery of drug candidates. Protein production, biophysics and X-ray crystallography are integrated with state-of-the-art medicinal chemistry capabilities to create a productive platform for the delivery of high-quality leads.
Sprint Bioscience operates in the high-class facilities at the campuses of Karolinska Institutet and KTH Royal Institute of Technology, Stockholm. We establish close links between disciplines and work by a dynamic project model with frequent decision points.[/td_text_with_title]
Sprint Bioscience AB (publ) (Sprint Bioscience) and Bayer HealthCare (Bayer) have entered into a collaboration and license agreement for the research, development, and commercialization of oncological drug candidates. Under the agreement, Sprint Bioscience licenses an early-stage inhibitor program targeting tumor metabolism to Bayer. Subsequently, Bayer will have full control over further development and worldwide commercialization rights for […]